T细胞受体
生物
基因组学
计算生物学
细胞毒性T细胞
抗原
癌症
T细胞
癌症研究
癌症免疫疗法
遗传学
受体
核糖核酸
基因
生物信息学
癌细胞
基因组
比较基因组学
人类基因组
免疫学
DNA测序
嵌合抗原受体
免疫
免疫疗法
功能基因组学
作者
Emily K. Jackson,Fu Luo,Jared L. Dietze,Christian Yee,Amber Martin,Daniella Tatang,Gavin M. Palowitch,Hannah I. Miller,Dinesh Manandhar,Yuxin Hao,Ekaterina Esaulova,Charles L. Dulberger,Benjamin P. Roscoe,Maria Massaro,Nicholas M. Ward,Tyler Nicholson,Matthew C. Funsten,Sandina Gnoth,Sebastian Newrzela,Stephanie LaHaye
标识
DOI:10.1126/scitranslmed.aeh8192
摘要
T cell receptors (TCRs) can enable detection and elimination of cancer cells via recognition of cancer-specific peptides presented on human leukocyte antigen (HLA). We speculated that shared cancer antigens could be recognized by recurrent ("public") TCRs, which might be identifiable using statistical methods. Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing. Using data from ∼150,000 patient tumor samples, we identified TCR chains that were associated with well-known cancer antigens, including human papillomavirus, mutated KRAS, and CT83. We devised methods for pairing enriched TCR-α and TCR-β chain sequences and validated 44 TCRs across nine peptide-HLA targets for antigen recognition, including potent cytotoxic TCRs. Our results suggest that public anticancer TCRs are common and may represent a new source for the development of cancer therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI